Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
239
resultados
Última actualización
15/07/2026 [07:04:00]
Resultados 225 a 239 de 239
Resumen de: WO2024254147A1
The present disclosure relates, in part, to a polypeptide of formula (I), or a salt or solvate thereof, and a vaccine composition thereof further comprising at least one pharmaceutically acceptable excipient. The present disclosure further relates to isolated mRNA and/or isolated polynucleotides encoding the polypeptide of formula (I), vectors and/or LNPs comprising the same, and pharmaceutical compositions thereof. The present disclosure further relates to methods of treating, preventing, and/or ameliorating a bacterial infection, and/or generating immunity to infection by one or more pathogenic bacteria, in a subject in need thereof, the method comprising administering to the subject at least one composition of the present disclosure. In certain embodiments, the bacterial infection is a urinary tract infection, sepsis (e.g, neonatal sepsis), or pneumonia.
Resumen de: WO2024254212A2
The present invention relates to anti-VISTA antibody RNA or nucleic acid conjugates (ARCs or ANCs) which specifically deliver at least one nucleic acid, e.g., RNAs into immune cells and the use of such ARCs or ANCs as therapeutics, e.g., for treating autoimmune, allergic and inflammatory conditions, or for treating cancer and/or for treating inflammatory symptoms associated therewith elicited by specific immune cell types which express VISTA.
Resumen de: CN119143620A
The invention provides a rapidly metabolized lipid compound, and particularly relates to a compound as shown in formula (I), or pharmaceutically acceptable salt, isotope variant, tautomer or stereoisomer thereof. The invention also provides nanoparticle pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions thereof in delivery of nucleic acids. # imgabs0 #
Resumen de: WO2024256962A1
The invention relates to RNA molecules encoding an E. coli fimbrial H antigen (FimH). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA 5 molecules, RNA-LNPs and compositions for the prevention of E. coli infection, including urinary tract infection.
Resumen de: WO2024255823A1
The present application relates to the field of biomedicine, and provides an epigenetic editing tool for targeting a hepatitis B virus gene and a use thereof.
Resumen de: WO2024254703A1
The blood-brain barrier (BBB) and the blood-cerebrospinal fluid (CSF) barrier (BCSFB) create an obstacle for effective systemic drug delivery to the CNS. This application provides compounds and nanoparticles for increasing the penetration of drugs through the BBB. Specifically, this application provides nanoparticles for the diagnosis and treatment of central nervous system (CNS) diseases and preparation methods therefor. These nanoparticles are polymer-lipid based nanoparticles (PLNPs) functionalized to facilitate blood brain barrier (BBB) penetration and accumulation in a disease area of the CNS. Notably, said nanoparticles target an LDL receptor and/or glucose transporter. In various embodiments, the nanoparticles comprise terpolymers which comprise polysorbates (such as polysorbate 80), poly acrylic acids (such as poly methacrylic acid (PMAA)) and various polysaccharides (including maltodextrin) and the nanoparticles also comprise cholesterol and lipids. The nanoparticles encapsulate a pay load which is a therapeutic drug molecule, biomolecule, contrast agent or nucleotide.
Resumen de: WO2025061835A1
The present invention relates to oligoglycerol-containing lipids and in particular to cationic or cationizable oligoglycerol-containing lipids and to a method for providing these oligoglycerol-containing lipids. Further, the present invention relates to liposomes, in particular thermosensitive liposomes comprising the novel oligoglycerol-containing lipids. Further the invention relates to liposomes comprising the novel oligoglycerol-containing lipids, which liposomes have an adjustable surface charge.
Resumen de: CA3137382A1
0001 Provided is a polymer comprising a hydrolysable polymer backbone, the polymer backbone comprising (i) monomer units with a side chain comprising a hydrophobic group; (ii) monomer units with a side chain comprising an oligoamine or polyamine; and optionally (iii) monomer units with a side chain comprising an ionizable group, as well as a method of preparing said polymer, and a method of delivering a nucleic acid and/or polypeptide to a cell using the polymer. 0002 L'invention concerne un polymère comprenant un squelette polymère hydrolysable, le squelette polymère comprenant (i) des unités monomères ayant une chaîne latérale comprenant un groupe hydrophobe; (ii) des unités monomères ayant une chaîne latérale comprenant une oligoamine ou une polyamine; et facultativement (iii) des unités monomères ayant une chaîne latérale comprenant un groupe ionisable, ainsi qu'une méthode de préparation dudit polymère, et une méthode d'administration d'un acide nucléique et/ou d'un polypeptide à une cellule à l'aide du polymère.
Resumen de: WO2021217267A1
The disclosure pertains to single chain antibodies, nucleic acids and vectors that encode antibodies that for example specifically bind W68 in the context of DAGWGNL (SEQ ID NO: 1) and methods of administering the single chain antibodies, nucleic acids and vectors to a subject in need thereof.
Resumen de: WO2025074292A2
The invention relates to lipid nanoparticles, immunogenic compositions and methods for use thereof.
Resumen de: US2025114306A1
0000 The present disclosure provides unshielded lipid nanoparticles and a process that enables the production of such unshielded lipid nanoparticles, thereby overcoming previous challenges of making particles without causing aggregation thereof. The lipid nanoparticles comprise a nucleic acid cargo molecule; a sterol or a derivative thereof present at a content of at least 12 mol %; a neutral lipid, such as a phospholipid having a choline head group present at a content of between 22 mol % and 65 mol %; and an ionizable cationic amino lipid present at a content of between 15 mol % and 45 mol %; wherein the lipid nanoparticle is non-sterically stabilized with a hydrophilic polymer-lipid conjugate, or otherwise unshielded and wherein each mol % content is relative to total lipid present in the lipid nanoparticle.
Resumen de: CN122301808A
本发明属于药物化学领域，具体涉及用于核酸递送的可电离磷脂及其应用。本发明要解决的技术问题是目前制备LNP递送mRNA的可电离磷脂种类较少。本发明解决技术问题的技术方案为提供一种新的可用于制备核酸递送载体的可电离磷脂分子及以之为基础制备的LNP制剂。以本发明可电离磷脂为原料制备的LNP制剂稳定性良好。实验表明，本发明LNP能高效递送治疗性RNA至多种人源和鼠源的肿瘤细胞中并实现高水平的蛋白表达，具有独特的优势，在本领域具有很好的应用前景。
Resumen de: WO2025090565A1
Methods and compositions for rejuvenating and reprogramming stem cells are disclosed. The methods involve administering to a subject an ABCB5 targeted composition comprising an anti-ABCB5 antibody conjugated to a therapeutic payload comprised of an epigenetic reprogramming factor or a nucleic acid encoding an epigenetic reprogramming factor in an effective amount to reprogram and rejuvenate ABCB5+ stem cells in the subject. The compositions include anti-ABCB5 antibody conjugated to a therapeutic payload comprising an epigenetic reprogramming factor or a nucleic acid encoding an epigenetic reprogramming factor.
Nº publicación: KR20260100690A 30/06/2026
Solicitante:
일라이릴리앤드캄파니유니버시다데데산티아고데콤포스텔라
Resumen de: WO2025085881A1
Nanoemulsions (NEs) and nanocapsules (NCs), are disclosed that include nanoparticles that can readily diffuse/distribute throughout the nervous system and that can deliver a therapeutic agent thereto. Methods of making and using the same also are disclosed, especially for treating diseases and/or disorders in which delivery of a therapeutic agent to and/or throughout the nervous system are needed.
BOPI
Sede Electrónica
